Skip to main content
VISIT JANSSEN GLOBAL
 
 
 

EMEA
change location▼

Search
Search
COVID-19 UPDATES >

Welcome to Janssen Europe, Middle-East and Africa

VISIT JANSSEN GLOBAL

Janssen EMEA › Media Center

Media Center

The Media Center is intented to provide resources for media professionals only. It is not inteded for use by healthcare professionals, patients or the general public. To access, please confirm that you are an accredited member of the press. I hereby confirm that I am an accredited member of the press
I Agree
Cancel

Press Releases

Jul 01, 2020

Johnson & Johnson Announces European Commission Approval for Janssen’s Preventive Ebola Vaccine

Jun 15, 2020

Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidate; Phase 1/2a Clinical Trial to Begin in Second Half of July

Jun 15, 2020

Subcutaneous Formulation of DARZALEX®▼(Daratumumab) Combination Resulted in Deep and Rapid Haematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis

Jun 15, 2020

New Phase 3 Data for TREMFYA®▼ (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, Show Consistent, High Levels of Skin Clearance Through Four Years in Adult Patients with Moderate to Severe Plaque Psoriasis

Jun 04, 2020

European Commission Grants Marketing Authorisation for DARZALEX®▼(daratumumab) Subcutaneous Formulation for all Currently Approved Daratumumab Intravenous Formulation Indications

Jun 03, 2020

New First-in-Class Phase 3 TREMFYA®▼ (guselkumab) Data Demonstrate Improvement in Psoriatic Arthritis Joint and Skin Symptoms at Week 52

View more Press Releases

Media Backgrounders

Neuroscience Backgrounder

Schizophrenia Backgrounder

Waldenström’s Macroglobulinemia (WM)

Stelara MOA infographic

The Role Of The Immune System In Crohn’s Disease

About Crohn’s Disease Backgrounder

VIEW MORE MEDIA BACKGROUNDERS

VIRTUAL ONCOLOGY PRESSROOM

Quick Links

 

Tweets

 
Follow us on Twitter
SUBSCRIBE TO OUR YOUTUBE CHANNEL